Cancer Letters
Volume 286, Issue 1 , Pages 15-21 , 1 December 2009

Control of hepatocellular carcinoma through Hepatitis B vaccination in areas of high endemicity: Perspectives for global liver cancer prevention

  • Amelie Plymoth

      Affiliations

    • International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
    • ,
  • Simonetta Viviani

      Affiliations

    • International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
    • Meningitis Vaccine Project, PATH Europe, Ferney-Voltaire, France
    • ,
  • Pierre Hainaut

      Affiliations

    • International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
    • Corresponding Author InformationCorresponding author. Fax: +33 4 72 73 83 22.

References 

  1. WHO . Hepatitis B vaccines. Wkly. Epidemiol. Rec. 2004;79:255–263
  2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 2006;28:112–125
  3. Lin DB, Wang HM, Lee YL, Ling UP, Changlai SP, Chen CJ. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine. 1998;16:1683–1687
  4. Sung JL, Chen DS, Lai MY, Wang TH, Wang CY, Yu JY, et al. Hepatitis B e antigen and antibody in asymptomatic Chinese with hepatitis B surface antigenemia in Taiwan. Gastroenterol. Jpn. 1982;17:341–346
  5. Whittle HC, Bradley AK, McLauchlan K, Ajdukiewicz AB, Howard CR, Zuckerman AJ, et al. Hepatitis B virus infection in two Gambian villages. Lancet. 1983;1:1203–1206
  6. Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine. 1998;16(Suppl.):S104–S108
  7. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–1133
  8. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39:211–219
  9. Ryder RW, Whittle HC, Sanneh AB, Ajdukiewicz AB, Tulloch S, Yvonnet B. Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts. Am. J. Epidemiol. 1992;136:1122–1131
  10. McMahon BJ. Skriv ut: natural history of chronic hepatitis B – clinical implications. Medscape J. Med. 2008;10:91
  11. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer. 2006;118:3030–3044
  12. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005;55:74–108
  13. Coursaget P, Yvonnet B, Chotard J, Vincelot P, Sarr M, Diouf C, et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J. Med. Virol. 1987;22:1–5
  14. Ekra D, Herbinger KH, Konate S, Leblond A, Fretz C, Cilote V, et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d’Ivoire. Vaccine. 2008;26:2753–2761
  15. Whittle H, Inskip H, Bradley AK, McLaughlan K, Shenton F, Lamb W, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J. Infect. Dis. 1990;161:1112–1115
  16. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N. Engl. J. Med. 1975;292:771–774
  17. Lin HH, Wang LY, Hu CT, Huang SC, Huang LC, Lin SS, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J. Med. Virol. 2003;69:471–474
  18. Leuschner I, Harms D, Schmidt D. The association of hepatocellular carcinoma in childhood with hepatitis B virus infection. Cancer. 1988;62:2363–2369
  19. Lee CL, Ko YC. Survival and distribution pattern of childhood liver cancer in Taiwan. Eur. J. Cancer. 1998;34:2064–2067
  20. Bah E, Hall AJ, Inskip HM. The first 2 years of the Gambian National Cancer Registry. Br. J. Cancer. 1990;62:647–650
  21. J. Ferlay, F. Bray, P. Pisani, D. Parkin, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5 (2004).
  22. Ni YH, Chang MH, Hsu HY, Hsu HC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis. Cancer. 1991;68:1737–1741
  23. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?. Hepatology. 2004;40:790–792
  24. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2:1099–1102
  25. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257:2597–2603
  26. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N. Engl. J. Med. 1997;336:1855–1859
  27. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann. Intern. Med. 2001;135:796–800
  28. Chang MH. Hepatitis B vaccination and control of hepatitis B-related liver disease. J. Pediatr. Gastroenterol. Nutr. 2000;31:112–117
  29. Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop. Med. Int. Health. 2006;11:1496–1502
  30. Jutavijittum P, Jiviriyawat Y, Yousukh A, Hayashi S, Toriyama K. Evaluation of a hepatitis B vaccination program in Chiang Mai, Thailand. Southeast Asian J. Trop. Med. Public Health. 2005;36:207–212
  31. Coursaget P, Leboulleux D, Soumare M, le Cann P, Yvonnet B, Chiron JP, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepatol. 1994;21:250–254
  32. Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, et al. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981;1:289–292
  33. Centers for Disease Control and Prevention . Progress in hepatitis B prevention through universal infant vaccination – China, 1997–2006. MMWR Morb. Mortal Wkly. Rep. 2007;56:441–445
  34. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J. Infect. Dis. 2000;181:413–418
  35. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine. 2001;19:3912–3918
  36. Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J. Infect. Dis. 2007;195:5–11
  37. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics. 2007;120:e373–381
  38. Poovorawan Y, Theamboonlers A, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine. 2000;19:943–949
  39. Aspinall S. Effectiveness of a low-cost hepatitis B vaccine in the South African EPI programme: field trial results. Epidemiol. Comments. 1995;22:8–10
  40. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine. 2001;19:3919–3926
  41. Sun Z, Zhu Y, Stjernsward J, Hilleman M, Collins R, Zhen Y, et al Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect. Prev. 1991;15:313–318
  42. Hall A, Inskip H, Loik F, et al. The Gambia hepatitis intervention study. The Gambia hepatitis study group. Cancer Res. 1987;47:5782–5787
  43. Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ. 2002;325:569
  44. Hall A, Inskip H, Loik F, et al. Hepatitis B vaccine in the expanded programme of immunisation: The Gambian experience. The Gambia hepatitis study group. Lancet. 1989;1:1057–1059
  45. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective?. J. Infect. Dis. 1999;179:489–492
  46. Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet. 1993;341:1129–1131
  47. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. 1999;17:2946–2950
  48. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE. 2007;2:e753
  49. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, et al. 20 Years into the Gambia hepatitis intervention study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol. Biomar. Prev. 2008;17:3216–3223
  50. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin. Drug Saf. 2003;2:225–231
  51. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J. Infect. Dis. 2006;193:1528–1535
  52. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch. Dis. Child Fetal Neonatal Ed. 1997;77:F47–51
  53. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332:328–336(Epub 2006 January, 2027)
  54. WHO . Meeting of the immunization strategic advisory group of experts, November 2008 – conclusions and recommendations. Wkly. Epidemiol. Rec. 2009;84:1–16
  55. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040–3042
  56. Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int. 2005;25:201–213

PII: S0304-3835(09)00551-5

doi: 10.1016/j.canlet.2009.08.024

Cancer Letters
Volume 286, Issue 1 , Pages 15-21 , 1 December 2009

Article Tools